Lysosomal dysfunction is implicated in human heart failure for which ischemic heart disease is the leading cause. Altered myocardial expression of CTSD (cathepsin D), a major lysosomal protease, was observed in human heart failure, but its pathophysiological significance has not been determined.
I
ntracellular protein degradation takes place primarily in proteasomes and lysosomes. Proteasomal and lysosomal dysfunctions are associated with cardiac pathogenesis, but the pathophysiological significance of these changes remains poorly understood. 1 Substrates are delivered to, and degraded by, lysosomes through either heterophagy or autophagy. Autophagy is further classified into microautophagy, chaperonemediated autophagy, and macroautophagy, 1 of which only macroautophagy requires formation of autophagosomes to send cargos to lysosomes. Although microautophagy and chaperone-mediated autophagy in cardiomyocytes are rarely studied, macroautophagy (hereafter referred to as autophagy) has been extensively investigated for its involvement in cardiac health and disease. 2, 3 However, it is worthy note that among the many reports on alterations of cardiac autophagy, only a few have emphasized that inadequate lysosomal degradation could be a potential underlying cause for the observed increases in autophagosomes. [4] [5] [6] [7] [8] [9] This is because the concept autophagic flux was not widely recognized then and, as a result, it often was not vigorously assessed. 10 Cargo digestion within lysosomes relies on lysosomal hydrolases. The most important lysosomal hydrolases are protease cathepsins. 11 Cathepsins are subdivided into 3 subfamilies based on the active site amino acids: the serine proteases cathepsin A and cathepsin G, the aspartic proteases CTSD (cathepsin D) and cathepsin E, and the cysteine cathepsins (ie, cathepsins B, C, F, H, K, L, O, S, V, X, and W). 12 Several cathepsins were investigated for their cardiac roles using genetically modified animal models. For example, Ctsl deficiency was shown to hasten cardiac remodeling and dysfunction after myocardial infarction (MI) and exacerbate cardiac pathology induced by aortic constriction in mice 13, 14 ; whereas knockout of Ctsb or Ctsk displayed protection against pressure overload-induced maladaptive cardiac remodeling. 15, 16 Ctsk deficiency also attenuated aginginduced cardiac dysfunction and high-fat diet-induced cardiac hypertrophy and malfunction in mice. 17, 18 These studies indicate that the role of different cathepsins in cardiac pathogenesis varies and must be determined individually.
CTSD is ubiquitously and abundantly expressed cathepsin, synthesized in the rough endoplasmic reticulum as pre-procathepsin D that contains a signal peptide targets the 52 kD procathepsin D (CTSD-p [CTSD precursor]) to the endosomal-lysosomal pathway. 19, 20 Removal of the 44 amino acid N-terminal propeptide produces the 48 kD intermediate form, and a further proteolytic cleavage results in the CTSD mature form (CTSD-m) consisting of a 34-and 14-kD chain. 20 With the creation of Ctsd global knockout mice, 21 CTSD has been studied for its role in immune homeostasis, 22 apoptosis, 23 cancer development, 24, 25 neurodegeneration, 26, 27 and retina diseases. 28 Changes in myocardial CTSD expression are also frequently used as an indicator of autophagic activity, assuming a key role for CTSD in lysosomal degradation of autophagosomes [29] [30] [31] ; however, this assumption has not been formally tested.
A potentially significant involvement of CTSD derangement in cardiovascular pathophysiology has been suggested by clinical observations. For examples, decreased myocardial CTSD protein levels in human dilated cardiomyopathy and increased plasma levels of CTSD in patients with acute coronary syndrome were reported 32, 33 ; furthermore, a higher level of serum CTSD was associated with atherogenesis, 34 increased risk of coronary events, 35 carotid intima-media thickness, 36 and endothelial dysfunction. 37 However, important questions on how CTSD deficiency affects cardiac function and whether the altered myocardial CTSD expression plays an important role in cardiac pathogenesis remain unanswered. Hence, we sought to address them in this study.
Here, we demonstrate that myocardial CTSD-p but not CTSD-m proteins are increased in human endstage heart failure (HF) resulting from ischemic heart disease (IHD) and in mouse model of chronic MI, CTSD is required for autophagosome removal and thereby
WHAT IS KNOWN
• Myocardial levels of lysosomal protease CTSD (cathepsin D), but not cathepsin B or K, were increased in explanted failing human hearts with ischemic heart disease, and these changes were recapitulated in a chronic myocardial infarction mouse model. • Through global knockout of the Ctsd gene, we showed that CTSD deficiency impairs myocardial autophagy and causes restrictive cardiomyopathy in mice.
• Autophagic activity is increased in the post-myocardial infarction hearts, and this increase is associated with an upregulation of CTSD.
• Preventing the heart from upregulating CTSD during myocardial infarction exacerbates adverse cardiac remodeling and dysfunction in mice.
WHAT THE STUDY ADDS
• Lysosomal dysfunction is implicated in human heart failure because of ischemic disease.
• Cathepsins are the proteases responsible for protein degradation in lysosomes.
• Deficiency of cathepsin D, found in explanted heart from patients with advanced ischemic heart disease, was shown to contribute to adverse myocardial remodeling in a mouse model. • Our findings suggest that decreases in CTSD activity would be detrimental in ischemic heart disease.
promotes autophagic flux in mouse hearts, myocardial CTSD upregulation induced by MI protects against post-MI cardiac remodeling and malfunction, and this protection is at least in part through increasing myocardial autophagic flux.
METHODS

Human Myocardial CTSD Detection
Left ventricular (LV) free wall tissues were collected from explanted human hearts with end-stage HF resulting from IHD during cardiac transplantation using a standardized protocol. Informed consent was obtained at the time each subject was listed for transplant. Four nonfailing controls without a history of cardiac diseases were procured from brain-dead organ donors whose hearts were deemed unacceptable for transplantation. Informed consent for research use of these hearts was obtained from the appropriate next kin by the organ procurement organization (Gift of Life, Inc., Philadelphia, PA). All hearts were arrested in situ with ice-cold cardioplegia solution (Viaspan, DuPont, Wilmington, DE), transported to the laboratory on wet ice, snap-frozen in liquid nitrogen within 2 hours, and stored at −80°C until protein extraction was performed. The research protocol was approved by the institutional review board at the University of Minnesota. All research was conducted in compliance with Good Clinical Practice standards and all applicable National Institutes of Health research requirements. For Western blot analyses, crude proteins were extracted using the radioimmunoprecipitation assay buffer.
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Animal Models
Creation of mice with germline ablation of Ctsd was reported. 21 The Ctsd +/− mice were maintained in the C57BL/6 inbred background. 
Western Blot Analyses
Western blot analyses for specific proteins in myocardium were performed as previously described.
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Immunofluorescence Confocal Microscopy
Cryosections of 4% paraformaldehyde fixed ventricular myocardium were processed for immunofluorescence staining of CTSD and confocal microscopy as we previously described. 40 
Autophagic Flux Assay
Mice were intraperitoneally injected with bafilomycin-A1 (BFA1, LC Laboratories; 1.868 mg/kg) or vehicle control (dimethyl sulfoxide). At 1 hour after the injection, ventricular myocardium was sampled from the mice for Western blot analyses for LC3-II levels as previously described. 4 
Echocardiography
Two-dimensional echocardiogram-guided M-mode echocardiography was performed on anesthetized mice as previously described.
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Pressure-Volume Relationship Analyses
Mice anesthetized via inhalation of 2.5% isoflurane were orally intubated and mechanically ventilated. A 1.4F Millar Mikro-Tip catheter transducer (model SPR-839, Millar Instruments) was inserted into the right common carotid artery and advanced to the LV chamber. After stabilizing for 30 minutes, LV pressure and volume were recorded; the other parameters were derived from the PowerLab software. 40 Both saline calibration and cuvette calibration were applied before data exportation.
Infarct Scar Size Determination
Perfusion fixed LV was processed to obtain 5-μm cryosections. Masson trichrome staining (Thermo Scientific kit) was conducted on LV cross-sections at the papillary muscle level, and digital images were captured with a microscope. The fibrotic area (ie, the infarct scar size)-stained blue was measured using ImagePro Plus 6.0 software. The percentage of scar size was calculated as reported.
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Statistics
Western blot densitometry data are presented as dot plots with mean±SEM superimposed, where differences between 2 groups or among multiple groups were evaluated in SPSS for statistical significance using, respectively, unequal variance t test or Welch ANOVA followed by Games-Howell test. Statistical tests for other results are specified table footnotes or figure legends. P<0.05 was considered statistically significant.
RESULTS
Alterations of Myocardial CTSD Proteins in HF Resulting From IHD
Myocardial expression of cathepsins has not been well studied in IHD. Hence, we measured myocardial CTSB, CTSD, and CTSK protein levels in explanted human hearts with IHD. Western blot analyses revealed a significant increase in CTSD-p but not the CTSD-m in human HF resulting from IHD compared with the nonfailing donor hearts ( Figure 1A-1C) . However, no significant changes in CTSB or CTSK were discerned in the same human samples ( Figure I in the Data Supplement). We also measured myocardial CTSB, CTSD, and CTSK proteins in a mouse model of surgically induced MI. The results show that myocardial Ctsd-p and Ctsd-m were significantly increased at 7 and 14 days after MI, and in agreement with the findings from human IHD, CTSD-p remained increased but the CTSD-m returned to a level only modestly higher than the sham control level by 28 days after MI when more severe HF was evident ( Figure 1D-1F ). CTSB proteins were also markedly increased while mature CTSK was slightly decreased (P<0.01) at 7 days after MI; however, both returned to the sham control level by 28 days after MI (Figures II and III in the Data Supplement).
Semiquantitative reverse transcription polymerase chain reaction analyses showed that myocardial Ctsd mRNA levels in the infarct zone and in the remote area at 7 days after MI were ≈6.5-and 4-folds of those in the sham controls ( Figure IV in the Data Supplement). Immunofluorescence confocal microscopy reveals that the increases of CTSD proteins are evident in both the infarct zone and the remote area where CTSD is primarily located in cardiomyocytes ( Figure 1G ). Taken together, the data from both humans and animal experiments consistently show an upregulation of cardiac CTSD-p in HF resulting from IHD, prompting us to determine the pathophysiological significance of CTSD derangement. 
Ctsd Is Required for Autophagosome Removal in Mouse Hearts
Although Ctsd null mice were characterized for noncardiac defects, the role of Ctsd in autophagy remains obscure. To test whether Ctsd participates in autophagosome removal, we performed myocardial LC3-II flux assay in Ctsd +/− , Ctsd +/− , and Ctsd +/+ littermate mice at baseline. Ctsd +/− mice displayed ≈50% reduction of all forms of CTSD proteins in the heart compared with Ctsd +/+ mice, and, as expected, neither CTSD-p nor CTSD-m was detectable in Ctsd −/− mice (Figure 2A-2C) . Importantly, myocardial LC3-II in Ctsd −/− mice was significantly increased ( Figure 2D and 2E and data not shown). To decipher the cause of the LC3-II increase, we treated the mice with BFA1, an inhibitor of the vacuolar proton ATPase that is known to inhibit lysosomal function and the fusion between autophagosomes and lysosomes. 43 We found that myocardial LC3-II were significantly increased at 1 hour after BFA1 administration in both wild-type and Ctsd +/− mice, but this increase was modest in Ctsd −/− mouse ( Figure 2D and 2E); meanwhile, there was no significant difference in myocardial LC3-II levels among the 3 genotypes treated with BFA1. These data indicate that myocardial autophagic flux is severely decreased by Ctsd deficiency, and Ctsd indeed plays an essential role in removing autophagosomes in the heart.
Ctsd −/− Mice Develop Restrictive Cardiomyopathy
The neural, endocrinal, digestive, and immunologic phenotypes of Ctsd deficient mice were widely studied systems 20, 21, 44 ; however, the impact of Ctsd deficiency on the cardiovascular system surprisingly has not been reported. Despite 50% reduction of myocardial CTSD proteins (Figure 2) , Ctsd +/− breeder mice at baseline did not display any discernible gross abnormality at least for their first 10 months of age, but Ctsd −/− mouse lifespan is <4 weeks ( Figure V in the Data Supplement), in agreement with previous reports. 21 Echocardiography studies revealed significant decreases in LV end-diastolic and end-systolic dimensions and volumes (P<0.001) and in stroke volume (P<0.01) in Ctsd −/− mice compared with the Ctsd +/+ littermate mice at 24 days of age; however, the ejection fraction (EF), fractional shortening (FS), and posterior wall thickness were not discernibly altered. Echocardiography did not reveal any abnormality in the Ctsd +/− mice ( Figure 3 ; Figure VI in the Data Supplement). These data indicate that Ctsd deficiency causes restrictive cardiomyopathy.
Dynamic Changes in After MI Myocardial Autophagic Flux
Autophagy in post-MI hearts was studied in a few previous reports, but autophagic flux has not been vigorously examined. 30, 31, 45 Hence, we determined myocardial autophagic flux in wild-type mice at 7, 14, and 28 days after MI. The border zone of the infarct induced by left anterior descending coronary artery ligation and the equivalent area of sham control were harvested at 1 hour after intraperitoneal injection of lysosome inhibitor BFA1 or vehicle control. The BFA1 treatment significantly increased LC3-II in both sham and MI groups, indicative of the effective lysosomal inhibition by BFA1 and detectable clearance of autophagosomes in myocardium within the 1 hour duration. Among vehicletreated groups, although none of the post-MI groups showed significantly higher LC3-II than their sham controls, there is a tendency that LC3-II decreases from 7 to 28 days after MI, with the difference between 7 and 28 days after MI being statistically significant. Among BFA1-treated groups, LC3-II levels in all the MI groups were significantly higher than that in the sham controls, but there were no significant differences among the post-MI groups (Figure 4 ). Taken together, these results demonstrate that myocardial autophagic flux is persistently elevated within 28 days after MI.
Blocking CTSD Upregulation Exacerbates Post-MI Cardiac Remodeling and Malfunction in Mice
The role of CTSD upregulation in diseased hearts was unknown; hence, we sought to determine the impact of Ctsd haploinsufficiency on post-MI hearts. As revealed by examinations at 7 and 28 days after MI, myocardial Ctsd upregulation induced by MI was prevented in the Ctsd +/− mice ( Figure 5A -5F), and this blockage is more complete in the remote area than in the infarct zone ( Figure VII in the Data Supplement), which was associated with a larger scar size, greater ventricular weight to body weight ratio, and greater lung weight to body weight ratio at 28 days after MI in the Ctsd +/− MI group compared with the Ctsd +/+ MI group ( Figure 5G-5J ). Serial echocardiography performed immediately before and 1, 2, 3, and 4 weeks after left anterior descending coronary artery ligation revealed hastened progression of LV chamber dilatation and malfunction (greater 
Blocking CTSD Upregulation Impairs Autophagic Flux in Post-MI Hearts
As described earlier, Ctsd deficiency impairs myocardial autophagic flux (Figure 2) , and persistent increases of myocardial autophagic flux are evident in post-MI hearts (Figure 4) , which prompted us to examine the hypothesis that exacerbation of post-MI cardiac mal- Figure 4 , myocardial LC3-II flux at both 7 and 28 days post-MI was significantly increased in Ctsd +/+ mice; however, this increase was substantially attenuated by Ctsd haploinsufficiency ( Figure 7A-7D ), indicating that although Ctsd +/− does not affect autophagic flux at baseline, it diminishes the MI-induced increase in autophagic flux via impairing autophagosome removal. This conclusion is also supported by changes in p62/SQSTM1 protein levels, a known substrate of autophagy. At 28 days after surgery, myocardial p62 proteins, which were comparable in the sham control groups, were significantly 
DISCUSSION
In the present study, we have unveiled that myocardial CTSD-p, but not CTSB or CTSK proteins, is significantly upregulated in human end-stage HF resulting from IHD, which is also verified in mouse models of chronic MI. For the first time, the autophagic flux in post-MI hearts is directly measured, and the results support the notion that post-MI myocardial autophagic activity is significantly increased. Through testing Ctsd −/− mice, we demonstrate that CTSD plays an indispensable role in the removal of autophagosomes in the heart. Moreover, we have established that MI-induced myocardial CTSD upregulation contributes to the enhanced autophagy and protects against post-MI ventricular remodeling and HF progression.
CTSD Deficiency Impairs Myocardial Autophagosome Removal and Causes Restrictive Cardiomyopathy
Lysosomes are responsible for the cargo removal in heterophagy and autophagy. As a major lysosomal aspartyl protease, CTSD is expected to play an important role in lysosomal proteolysis. Loss-of-function mutations of the CTSD gene are linked to human lysosome storage disease, such as neuronal ceroid lipofuscinosis type 10 26, 46 ; and mice with global or neuroectoderm-specific deletion of Ctsd display abnormalities that recapitulate main manifestations of human neuronal ceroid lipofuscinosis type 10 disease. 47 This, however, does not necessarily mean that CTSD is generally required for autophagic flux. There is evidence both for and against the notion that Ctsd is required for general autophagic flux. For example, increases in autophagosomes were observed in Ctsd null mouse brains, 48, 49 which is consistent with impaired autophagosome removal but is also interpreted by some as evidence for induction of autophagy by Ctsd deficiency. 49 However, inhibition of CTSD activity through overexpressing an inactive CTSD significantly decreased the degradation of endogenous α-synuclein but failed to mitigate autophagic flux in cultured SH-SY5Y cells 50 ; similarly, targeting Ctsd in mouse pancreatic acinar cells was reported to have no effect on autophagic activity. 51 To our best knowledge, no reported study had performed a definitive autophagic flux assay on any organ/tissue of the Ctsd null mice. Using the well-accepted LC3-II flux assay, we have found that at the baseline condition, myocardial autophagic flux is not discernibly altered in Ctsd +/− mice but is significantly impaired in Ctsd −/− mice because of defective removal of autophagosomes as evidenced by accumulation of LC3-II at baseline and failure of BFA1-mediated lysosomal inhibition to increase LC3-II (Figure 2) . Notably, Ctsd deficiency led to increases in CTSB, lysosome-associated membrane protein 1, and lysosome-associated membrane protein 2 in the heart (Figure X in the Data Supplement), which is in agreement with reports for other tissues/organs, 44, 51 but these presumably compensatory responses apparently fail to effectively compensate for Ctsd deficiency, demonstrating that Ctsd is indispensable for autophagosome removal in myocardium.
The autophagic impairment caused by Ctsd deficiency is not harmless to the heart because we have detected restrictive cardiomyopathy in Ctsd −/− mice as reflected by reduced end-diastolic volume and stroke volume with preserved EF and FS, in absence of cardiac hypertrophy ( Figure 3 ).
Myocardial CTSD-p Is Increased in IHD
Serum CTSD proteins or activity were always higher in post-MI humans than age-matched controls. 33, 52 As an alternate to renin, the increased CTSD may catalyze angiotensin II formation that is known to promote post-MI maladaptive cardiac remodeling. 52 However, post-MI patients with major adverse cardiovascular events showed a lower average serum CTSD activity than those without major adverse cardiovascular events during a 6-month follow-up. 33 It was unclear whether the post-MI increases in serum CTSD was accompanied by a reciprocal decrease of myocardial CTSD; now our results indicate that this is unlikely because we found significant increases in myocardial CTSD-p with CTSDm unchanged in humans with IHD ( Figure 1A-1C) . This IHD-associated change is also sharply different from what was reported for human dilated cardiomyopathy which showed a marked CTSD-m reduction, 32 but it is recapitulated in post-MI mouse hearts ( Figure 1D-1F) . In mice, myocardial CTSD-p proteins were increased throughout the first 4 weeks post-MI but CTSD-m, which was elevated at 1 and 2 weeks post-MI, returned to the sham control level at 4 weeks post-MI ( Figure 4E) . Notably, myocardial CTSB was markedly increased while mature CTSK was decreased at 7 days post-MI but neither was altered at 28 days post-MI in mice, which is consistent with the results from explanted human hearts with IHD. These findings indicate that cardiac changes of cathepsins during IHD are isoform dependent, and the change of individual isoforms (eg, CTSD and CTSK) in the failing hearts is pathogenesis specific because myocardial CTSD was shown to decrease and CTSK to increase in human HF resulting from idiopathic dilated cardiomyopathy. 16 ,32
MI-Induced CTSD Upregulation Promotes Autophagic Flux and Protects Against Cardiac Remodeling and Malfunction
Here, we have determined for the first time the effect of blocking CTSD upregulation on the progression of post-MI cardiac remodeling and HF. The MI-induced increases in myocardial CTSD proteins were completely prevented by Ctsd heterozygous knockout ( Figure 5 ), which exacerbated post-MI LV chamber dilatation, decreases in EF and FS (Figure 6 ), the depression of LV contractile and relaxation function and cardiac output (Table) , and pulmonary congestion and increased scar size ( Figure 5 ). These results compellingly demonstrate that MI-induced CTSD upregulation confers protection against post-MI cardiac remodeling and malfunction.
Several previous studies have shown increases in autophagosome abundance in ischemic myocardium 30, 31, 45 ; here, our LC3-II flux assay results ( Figure 4 ) reveal explicitly for the first time that the increases are indeed caused by autophagic activation. Increased expression of CTSD was frequently used as an evidence of enhanced autophagy [29] [30] [31] ; however, the role of CTSD upregulation in promoting autophagy in diseased hearts has not been established until the present study. Blocking CTSD upregulation via Ctsd haploinsufficiency abolished the post-MI increase of myocardial autophagic flux via limiting the removal of autophagosomes (Figure 7) , demonstrating that the CTSD upregulation is indispensable to increasing autophagic flux in post-MI hearts.
Studies manipulating cardiac autophagy have overwhelmingly shown a protective role for increased autophagy against myocardial ischemic injury and post-MI remodeling likely via promoting protein and organelle quality control. 30, 31, 45 Taken together, our data indicate that IHD-induced upregulation of myocardial CTSD is critically adaptive, and this protection is at least in part through promoting myocardial macroautophagy. Conceivably, it is likely that CTSD upregulation could also enhance other aspects of lysosomal function (eg, heterophagy and other forms of autophagy) but that remains to be tested in the future.
